- Conditions
- Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Wild-type Reovirus
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 6
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • The Bronx, New York + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 25
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Carcinoma, Squamous Cell of the Head and Neck
- Interventions
- REOLYSIN®, Carboplatin, Paclitaxel
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 2
- States / cities
- The Bronx, New York • San Antonio, Texas
- Conditions
- Osteosarcoma, Ewing Sarcoma Family Tumors, Malignant Fibrous Histiocytoma, Sarcoma, Synovial, Fibrosarcoma, Leiomyosarcoma
- Interventions
- REOLYSIN®
- Biological
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 4
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota • The Bronx, New York + 1 more
- Conditions
- Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
- Interventions
- Pembrolizumab, Wild-type Reovirus
- Biological
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Metastatic Melanoma
- Interventions
- REOLYSIN, Carboplatin, Paclitaxel
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Ras-mutated Metastatic Colorectal Cancer, mCRC, MSS Metastatic Colorectal Cancer
- Interventions
- Bevacizumab, FOLFIRI, Pelareorep
- Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 13
- States / cities
- Homewood, Alabama • Beverly Hills, California • Encino, California + 9 more
- Conditions
- Carcinoma, Squamous Cell of the Head and Neck
- Interventions
- REOLYSIN, Carboplatin, Paclitaxel, Placebo
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Burbank, California + 18 more
- Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Interventions
- wild-type reovirus, cyclophosphamide, laboratory biomarker analysis, pharmacological study
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
- Conditions
- Recurrent Melanoma, Stage IV Melanoma
- Interventions
- wild-type reovirus
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Childhood Astrocytoma, Childhood Atypical Teratoid/Rhabdoid Tumor, Diffuse Intrinsic Pontine Glioma, Glioma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Childhood Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Brain Neoplasm
- Interventions
- Laboratory Biomarker Analysis, Sargramostim, Wild-type Reovirus
- Other · Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Triple-negative Breast Cancer
- Interventions
- Pelareorep, Quality-of-Life Assessment, Questionnaire Administration, Retifanlimab
- Biological · Other
- Lead sponsor
- Mridula George, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 2
- States / cities
- New Brunswick, New Jersey • Columbus, Ohio
- Conditions
- Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
- Interventions
- REOLYSIN, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Ocala, Florida • Niles, Illinois + 13 more
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Wild-type Reovirus
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Breast Cancer Metastatic
- Interventions
- Paclitaxel, Pelareorep, Avelumab
- Drug · Biological
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 18
- States / cities
- Miami, Florida • Urbana, Illinois • Indianapolis, Indiana + 13 more
- Conditions
- Light Chain Deposition Disease, Refractory Plasma Cell Myeloma
- Interventions
- Diagnostic Laboratory Biomarker Analysis, Wild-type Reovirus
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Malignant Glioma
- Interventions
- REOLYSIN®
- Biological
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Los Angeles, California • Columbus, Ohio
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Bortezomib, Dexamethasone, Laboratory Biomarker Analysis, Pharmacological Study, Wild-type Reovirus
- Drug · Other · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis, Pelareorep
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Columbus, Ohio • Salt Lake City, Utah
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Interventions
- Laboratory Biomarker Analysis, Paclitaxel, Pelareorep
- Other · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 36
- States / cities
- Burbank, California • Mountain View, California • Hartford, Connecticut + 30 more
- Conditions
- Carcinoma, Non-small Cell Lung
- Interventions
- REOLYSIN®, Carboplatin, Paclitaxel
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Columbus, Ohio
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Bortezomib, Dexamethasone, Pelareorep, Pembrolizumab
- Drug · Biological
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- REOLYSIN®, Chemotherapy, Gemcitabine, Irinotecan, Leucovorin, 5-fluorouracil, Pembrolizumab
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Metastatic Pancreatic Adenocarcinoma
- Interventions
- REOLYSIN, Gemcitabine
- Biological · Drug
- Lead sponsor
- Oncolytics Biotech
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 2
- States / cities
- New York, New York • San Antonio, Texas
- Conditions
- Recurrent Plasma Cell Myeloma
- Interventions
- Carfilzomib, Dexamethasone, Nivolumab, Pelareorep
- Drug · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Salt Lake City, Utah